Scientific evidence of the benefits of virgin olive oil for human health

Evidencia científica de los beneficios del consumo de aceite de oliva para la salud humana

María-Isabel Covas1,2,3, Rafael de la Torre2,4, Montserrat Fitó1,2.
1Cardiovascular Risk and Nutrition Research Group, 2Human Pharmacology and Neurosciences Research Group, and 3CIBER de Fisiopatología de la Obesidad y la Nutrición, IMIM- Institut Hospital del Mar d’ Investigacions Mèdiques. 3NUPROAS (Nutritional Project Assessment) Handesbolag (NUPROAS HB). Nacka, Sweden.

Abstract

Olive oil is considered to be one of the most healthy dietary fats. There are, however, several types of olive oil present on the market. With the data at present available, the most healthy of them is the virgin olive oil (VOO), rich in phenolic compounds. On November 2011, the European Food Safety Authority (EFSA) released a claim concerning the benefits of the daily ingestion of olive oil rich in phenolic compounds, such as the VOO. In this review, we will summarize the work which have provided scientific evidence of the benefits of VOO consumption over other type of edible oils even olive oils. Data from randomized, controlled human studies, will be presented. This type of studies are able to provide evidence of Level I which is that required for performing nutritional recommendations at population level.

Key words: Virgin olive oil, benefits, nutritionial recomendations, tyrosol, hydroxytyrosol

Resumen

Se considera al aceite de oliva una de las grasas más saludables de la dieta. Hay, sin embargo, varios tipos de aceite de oliva presentes en el mercado. Con los datos actualmente disponibles, el más saludable de ellos es el aceite de oliva virgen (AOV), rico en compuestos fenólicos. En noviembre de 2011, la Autoridad Europea de Seguridad Alimentaria (EFSA) publicó un declaración acerca de los beneficios de la ingesta diaria de aceite de oliva rico en compuestos fenólicos, como el VOO. En esta revisión, vamos a resumir el trabajo que ha proporcionado la evidencia científica de los beneficios del consumo de AOV sobre otro tipo de aceites comestibles e incluso sobre los otros tipos de aceite de oliva. Presentamos, asimismo, los datos de estudios aleatorizados y controlados en humanos. Este tipo de estudios proporcionan evidencia de nivel I, que es el nivel requerido para ofrecer recomendaciones nutricionales a nivel poblacional.

Palabras clave: Aceite de oliva virgen, beneficios, recomendaciones nutricionales, tirosol, hidroxitirosol

Introduction

Olive oil is the primary source of fat in the Mediterranean diet which is associated with a low mortality for cardiovascular disease1. A large body of knowledge exists providing evidence of the benefits of olive oil consumption on secondary end points for cardiovascular disease2. On November 2004, the Federal Drug Administration (FDA) of the U.S.A permitted a claim on olive oil labels concerning: “the benefits on the risk of coronary heart disease (CHD) mortality and incidence3. An inverse relationship between olive oil consumption and stroke risk in women has been reported in the Three-City Study4.

Olive oil has major and minor components. The former are the fatty acids, of which the monounsaturated fatty acid (MUFA), the oleic acid, represents from 55% to 83% of the total fatty acids2. The minor components of olive oil constitute from 1% to 2% of the total content of an olive oil and are classified as: 1) the unsaponifiable fraction, which can be extracted with solvents after the saponifi-
fication of the oil and contains squalene and other terpenes, sterols, tocopherol, and pigments, and 2) the soluble fraction that includes the phenolic compounds, the complex forms called polyphenols. Phenolic compounds are present as simple phenols or conjugated forms (Figure 1). Tyrosol (Tyr), hydroxytyrosol (OHTyr), and their secoiridoid derivatives make up around 90% of the total phenolic content of a virgin olive oil. Phenolic compounds from olive oil are the most studied and best known components in terms of their benefits for health. The content of the minor components of an olive oil varies, depending on the cultivar, climate, ripeness of the olives at harvesting, and the processing system employed to produce the olive oil. Olive oils currently present on the market are: extra-virgin, virgin, olive oil (UE, 1991), or pomace (also called orujo) olive oil. Virgin olive oils (VOOs) are those obtained from the fruit of the olive tree solely by mechanical or other physical means under conditions that do not lead to alteration in the oil. Extra-VOOs are VOOs with a free acidity, expressed as g of oleic acid/100 g of olive oil, less than 0.8 g. VOOs with an acidity greater than or equal to 3.3 (International Olive Oil Council Regulation/ T.15/NC.n3.Rev2.Nov24, 2006) or greater than 2 in Europe (European Regulation N. 1513/0) are submitted to a refining process in which some components, mainly phenolic compounds, and to a lesser degree squalene, are lost. By mixing virgin and refined olive oil an ordinary olive oil (olive oil, UE 1991) is produced and marketed. After VOO production, the rest of the olive drupe and seed is submitted to a refining process, resulting in pomace olive oil, to which a certain quantity of VOO is added before marketing.

Here, we will summarize the key work which has provided evidence of the benefits of VOO consumption over other type of edible oils even olive oils. We will focus on data from randomized, controlled human studies, which are those capable to provide the evidence of Level I. On the basis of the Evidence-Based Medicine, evidence of Level I is which is required for performing nutritional recommendations at population level.

Metabolic disposition of olive oil phenolic compounds in humans from real-life doses of natural olive oils.

One of the prerequisites for assessing the physiological significance of olive oil phenolic compounds is the ability to determine their bioavailability in human beings. Tyr and OHTyr are absorbed by humans from olive oil in a dose-dependent manner with the phenolic content of the olive oil administered both after a single dose or after sustained olive oil consumption. This implies an accumulation in the body even from moderate doses of olive oil (25 mL/d) which are lower than the traditional daily dietary intake in Mediterranean countries (30-50g/day). The bioavailability of OHTyr, however, has been shown to change largely depending on the matrix in which the phenolic compounds are administered, the most effective matrix being the olive oil. Around 98% of Tyr and OHTyr are present in plasma and urine in conjugated forms, glucuronosyl conjugates or sulfates. This fact indicates the existence of an extensive first-pass intestinal/hepatic metabolism of the ingested primary forms.

Figure 1: Structures of the major phenolic compounds identified in olives and olive oil. A, hydroxytyrosol; B, tyrosol; C, oleuropein glucoside; D, dialdehydic form of oleuropein (SID-1); E, ligstroside (SID-2); F, aglycone form of oleuropein glucoside (SID-3); G, ligstroside SID-4; H, lignanes (+)-pinoresinol; I: (+)-1-acetoxypinoresinol.
Lipoproteins and Lipoprotein Oxidation

The replacement of saturated fatty acids (SFA) by oils enriched in MUFA versus polyunsaturated fatty acids (PUFA) had similar effects on lowering total and low density lipoproteins (LDL) cholesterol. The PUFA-enriched oil had a slight triglyceride lowering effect, and there was an increase in HDL cholesterol after MUFA consumption in some studies. There is, however, an issue in which MUFA consumption prevails over the PUFA one: the lipoprotein oxidation. Oleate-rich LDL are less susceptible against oxidation than linoleate-rich particles. This is due to the fact that PUFAs are the key substrate for lipid peroxidation whose propagation chain is going on via the double bonds of the fatty acid. From 14 studies comparing the resistance of LDL to oxidation only in 2 of them did MUFA-rich diets not promote a higher resistance of LDL to oxidation than PUFA-rich ones.

Oxidation of the lipid part, or directly of the apolipoprotein (apo) B, of the LDL leads to a change in the lipoprotein conformation by which the LDL is better able to enter into the monocyte/macrophage system of the arterial wall, and develop the atherosclerotic process. Oxidized LDL has been shown to be independently associated with 10-year coronary artery disease (CAD) events in the general population, and improved the reclassification capacity of Framingham-derived CAD risk functions.

Phenolic compounds present in VOO have proven to be protective against LDL oxidation. On November 2011, the European Food Safety Authority (EFSA) released a claim concerning the benefits of the daily ingestion of olive oil rich in phenolic compounds, such as the virgin olive oil. The Panel considers that in order to bear the claim, 5 mg of OH-Tyr and its derivatives (e.g., oleuropein complex and Tyt) in olive oil should be consumed daily. These quantities, if provided by moderate amounts of olive oil, can be easily consumed in the context of a balanced diet. Here we will revise the main studies which supported this EFSA claim concerning the benefits of phenolic compound-rich olive oil such as VOO.

Human studies of the sustained effect of olive oil on oxidative stress and oxidative damage

Controversial results have been obtained in short sample size (n<30) human randomized controlled studies performed up to now on the effect of sustained doses of olive oil phenolic compounds on oxidative stress. Extensive differences existed among the studies in the experimental design, control of diet, sample population, age of the participants, measurement or not of markers of the compliance of the intervention, as well as in the sensitivity and specificity of the oxidative stress biomarkers evaluated. This fact could explain the differences of results observed among studies.

The results of the EUROLIVE study, however, have provided final evidence of the in vivo protective role of phenolic compounds from olive oil on lipid oxidative damage in humans, at real-life olive oil doses. The EUROLIVE study was a large, crossover, multi-centre, clinical trial performed in 200 individuals from five European countries. Participants were randomly assigned...
to receive 25 mL/day of three similar olive oils, but with differences in their phenolic content (from 2.7 mg/kg to 366 mg/kg of olive oil), in intervention periods of 3 weeks preceded by 2 week washout periods. All olive oils increased the HDL-cholesterol and the ratio between the reduced and oxidized forms of glutathione. In the EUROLIVE study, consumption of medium- and high-phenolic content olive oil decreased lipid oxidative damage biomarkers such as plasma oxidized LDL, uninduced conjugated dienes, and hydroxy fatty acids, without changes in F2-isoprostanes. But the most important results of the EUROLIVE study were that the increase in HDL cholesterol and the decrease in the lipid oxidative damage were linear with the phenolic content of the olive oil consumed. The results of the EUROLIVE study provided first level evidence that olive oil is more than a MUFA fat.

Concerning DNA oxidative damage, the urinary excretion of 8-oxo-deoxyguanosine (dGuo) is advocated as a biomarker of the whole body DNA oxidation, a risk factor for cardiovascular and cancer diseases. A protective effect of phenolic compounds from VOO has been reported on in vivo DNA oxidation both in healthy male subjects and in postmenopausal women. Results of the EUROLIVE study, however, show that consumption of 25 mL of olive oil per day during 3 weeks reduced DNA oxidation in 182 healthy males, as measured by the 24 h urinary excretion of dGuo, irrespective of the olive oil phenolic content. Differences in the type of population involved (with or without oxidative stress) could explain differences among results. In this sense, one conclusion of the Consensus Report made by the Expert Panel in the International Conference of Olive Oil and Health held in Jaen, Spain, October 2004 was that the protective effects on oxidation markers in human trials were better displayed in oxidative stress conditions.

### Table I: Randomized controlled studies on the effect of VOO on inflammatory and vasculoprotective markers.

<table>
<thead>
<tr>
<th>Author, year (Reference)</th>
<th>Type of study</th>
<th>Subjects</th>
<th>Intervention</th>
<th>Biomarkers</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visioli et al. 200527</td>
<td>Randomized, crossover</td>
<td>Hyperlipidemic patients (12 men and 10 women)</td>
<td>VOO vs refined olive oil (intervention, 40 mL/d, 7 weeks; washout period, 4 weeks with usual diet)</td>
<td>Serum TBX2</td>
<td>Decrease with the phenolic content of the olive oil</td>
</tr>
<tr>
<td>Cubí &amp; etia 200118</td>
<td>2 consecutive periods, no washout, diets ad libitum</td>
<td>12 postmenopausal women</td>
<td>VOO vs oleic acid-rich sunflower oil</td>
<td>TXB2 in PRP TXB2 in urine 6-keto-PGF1-α</td>
<td>Lower in VOO Similar Similar</td>
</tr>
<tr>
<td>Bogni &amp; etia 200629</td>
<td>Randomized, crossover postprandial</td>
<td>12 healthy men</td>
<td>VOO vs refined olive oil (50 mL with potatoes)</td>
<td>Plasma LT B, Plasma TBX2</td>
<td>Decrease with the phenolic content of the olive oil</td>
</tr>
<tr>
<td>Fité &amp; etia 200830</td>
<td>Randomized, crossover</td>
<td>28 men with CHD</td>
<td>VOO vs refined olive oil (intervention period, 50 mL/d, 3 weeks; washout period 2 weeks with refined olive oil ad libitum)</td>
<td>hCRP, IL-6 Serum ICAM-1 and VCAM-11</td>
<td>Decrease with the phenolic content of the olive oil No changes</td>
</tr>
<tr>
<td>Moreno-Luna &amp; etia 201221</td>
<td>Randomized, crossover</td>
<td>24 women with high-normal BP or stage 1 essential hypertension</td>
<td>Rich polyphenol-VOO (30 mg/day) vs free polyphenol olive oil (2 month; 4-week washout period)</td>
<td>ADMA he-CRP</td>
<td>Decrease with the phenolic content of the olive oil</td>
</tr>
<tr>
<td>Pacheco &amp; etia 200722</td>
<td>Randomized, crossover, postprandial</td>
<td>Healthy (14) and hyper-triglyceremic (14) men</td>
<td>Fat meal with VOO vs refined olive oil, after 1 week of each (50 mg/m2 body surface)</td>
<td>Serum ICAM-1 and VCAM-1 area under curve</td>
<td>Decrease with the phenolic content of the olive oil</td>
</tr>
<tr>
<td>Pérez-Herrera &amp; etia 201223</td>
<td>Randomized, crossover postprandial</td>
<td>20 obese participants</td>
<td>Breakfast with VOO, sunflower oil (SFO) and SFO+canola oil (heated with added polyphenols or artificial antioxidants</td>
<td>TNF-α, IL-1β, IL-6, MIF, JNK, and LPS NFκB and subunits activators</td>
<td>Decrease with oils containing polyphenols and antioxidants</td>
</tr>
<tr>
<td>Windmer &amp; etia. 201334</td>
<td>Randomized, parallel</td>
<td>82 patients with early atherosclerosis</td>
<td>VOO+ and VOO+ EECG (30 mL/d, 4 months)</td>
<td>ICAM-1 White blood cells</td>
<td>Decrease with VOO</td>
</tr>
</tbody>
</table>

TXB2, thromboxane B2; 6-keto-PGF1-α, 6-keto-prostaglandin; PRP, platelet-rich plasma; LT B4, leukotriene B4; ICAM-1, intercellular adhesion molecule-1; VCAM-1, vascular cell adhesion molecule-1; CHD, coronary heart disease; hCRP, high sensitivity C reactive protein; IL-6, interleukin 6 ADMA, asymmetric dimethylarginine; TNF-α, tumour necrosis factor alpha; IL-1β, interleukin 1β; MIF, macrophage migration inhibitory factor; JNK, c-Jun Nterminal kinase; LPS, lipopolysaccharide.
compounds in humans (Table I). In these studies, VOO with high phenolic content has been shown to be effective in reducing the eicosanoid inflammatory mediators derived from arachidonic acid, such as thromboxane B2 and 6-keto-prostaglandin F1, as well as other inflammatory markers, such as high-sensitivity C-reactive protein or interleukin-6. A decrease of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) serum levels at postprandial state after VOO consumption in coronary heart disease (CHD) patients has been reported.

Also, the postprandial inflammatory response after ingestion of heated oils in obese persons was reduced by the presence of oils with phenolic compounds or non natural antioxidants. In this study, VOO or a mix of sunflower and canola oil artificially enriched with olive oil phenolic compounds and other antioxidants, lowered the postprandial nuclear factor κappa B (NF-κB) activation, increased NF-κB inhibitor (κB-α), and decreased lipopolysaccharide (LPS) plasma concentration, compared with sunflower oil. In sustained consumption studies, a decrease in ICAM-1 after VOO, but not after VOO plus epigallocatechin-3-galate (EGCG) in early atherosclerosis patients has been reported. However, no differences in ICAM-1 or VCAM-1 levels were reported after sustained virgin or refined olive oil consumption in coronary heart disease (CHD) patients.

Vasomotor, haemostatic, antioxidant, and inflammatory activities are involved in endothelial dysfunction, a recent focus of intense research in cardiovascular medicine. The effect of VOO reducing oxidative stress and oxidative damage, as well as the inflammatory markers has been described above. The postprandial prothrombinic profile improved in healthy subjects and hypercholesterolemic patients after intake of phenol-rich VOO versus a low-phenolic content olive oil. Several studies have reported beneficial effects of VOO on the endothelial function. An improved post-ischemic hyperemia via reduced oxidative stress and increased nitric oxide metabolites was reported after the intake of phenol-rich VOO in comparison with a low-phenol olive oil in hypercholesterolemic patients. The effect of VOO phenols on the postprandial endothelial function seems to be mediated by the NOS3 Glu298Asp polymorphism in patients with metabolic syndrome. Beneficial effects improving the endothelial function have been observed after a 4-month diet with polyphenol-rich olive oil in patients with early atherosclerosis.

Consumption of olive oil reduces blood pressure. However, phenolic compounds in VOO play also a beneficial role. A decrease in systolic (SBP) and diastolic blood pressure, with an improvement of endothelial function, has been reported after a 2-month diet with rich-polyphenol olive oil versus a low polyphenol one, in young women with mild hypertension. In this study, changes in blood pressure and endothelial function were concomitant with markers related with vasodilatation, such as an increase in nitric oxide and a decrease in serum asymmetric dimethylarginine, as well as a reduction in oxidized LDL and hsCRP. VOO, reduced SBP in hypertensive women and stable CHD patients in comparison with high-oleic sunflower oil and refined olive oil, respectively. In a parallel study comparing the effect of VOO on blood pressure in diabetic patients and healthy individuals, a reduction in SBP was observed in both conditions.

Mechanisms by which VOO and its phenolic compounds can exert their benefits in vivo in humans.

Although there is a huge body of experimental studies concerning mechanisms by which VOO and its phenolic compounds could exert their beneficial effects, up-to-date only two have been reported to occur in vivo in humans: 1) an increase of the antioxidant content of the LDL, and 2) a nutrigenomic effect.

Consumption of VOO increases the antioxidant content of the LDL

In human studies the best results obtained on lipid oxidation markers after VOO consumption are displayed in those markers directly associated with LDL. This was one of the conclusions of the Consensus Report made by the Expert Panel in the International Conference of Olive Oil and Health held in Jaen, Spain, October 2004. This could be explained on one hand by the fact that ingestion of any type of olive oil increases the plasma oleic acid content of the LDL lipoprotein. After olive oil ingestion, oleic acid concentration in LDL increased and those of linoleic and arachidonic acid decreased. As has been referred before, oleate-rich LDL are less susceptible against oxidation than linoleate-rich particles. On the other hand, the total polyphenol content bound to human LDL increases in a dose dependent manner with the phenolic content of the olive oil administered. OHTyr and Tyr metabolites, glucuronides and sulfates, have been reported to bind human LDL after VOO ingestion, but were not detected after refined olive oil ingestion. An inverse relationship between plasma levels of oxidized LDL and the content of phenols bound to LDL has been reported. Phenolic compounds which can bind LDL are likely to perform their peroxyl scavenging activity in the arterial intima, where full LDL oxidation occurs.

Nutrigenomic effect of VOO and its phenolic compounds

Nutrigenomics embrace all "omics" fields, such as genomics, transcriptomics, proteomics, and metabolomics with the aim of understanding and characterizing how nutrients and/or food act at molecular level. Here we will focus in the transcriptomic data available from human
studies, and in particular those studies in which different types of olive oils have been tested with the same dietary pattern as background. Several studies have examined the transcriptomic profile after VOO, in comparison with low phenolic content olive oil, both at postprandial state and after sustained consumption41. A breakfast based on VOO, high in polyphenols (398 ppm), was able to postprandially repress the expression of proinflammatory genes when compared with a common olive oil based breakfast (low in polyphenols, 70 ppm) in metabolic syndrome individuals. Microarray results showed 19 upregulated and 79 downregulated genes, linked to obesity, dyslipemia, and type 2 diabetes mellitus, after the intake of VOO41. A VOO enriched with its own phenolic compounds enhanced the postprandial expression of cholesterol efflux related genes in vivo in humans versus an standard VOO. In our pre- and stage I hypertensive patients, we observed an increase in ATP binding cassette transporter-A1 (ABCA1), scavenger receptor class B type1 (SR-B1), peroxisome proliferator-activated receptors and binding protein (PPARγ; PPARα; PPARγ2; PPARδ) and CD36 gene expression in white blood cells at postprandial after high polyphenol VOO when compared with standard VOO22.

Also within the frame of a Mediterranean diet (MeD), in a parallel, controlled, 3-month intervention trial, 90 healthy volunteers were randomized to three intervention dietary patterns: I) MeD supplemented with rich-polyphenol VOO (328mg/kg); II) MeD supplemented with washed VOO (low in polyphenols: 55 mg/kg); and III) habitual diet (control group). Only after the MeD supplemented with rich-polyphenol VOO there was a significant decrease, versus the control group, in the expression of inflammatory genes: interferon gamma (IFNγ), Rho GTPase activating protein 15 (ARHGAP15), and interleukin 7 receptor (IL7R); and oxidative stress: adrenergic b-2 receptor (ADRB2). Changes in gene expression after the MeD supplemented with VOO were concomitant with decreases in lipid oxidative damage and systemic inflammation markers22. In the frame of the PREDIMED study, two studies have reported differences when an enrichment of the MeD with VOO occurs. In the first44, a 3-month intervention with VOO-enriched MeD prevented the increase in cyclooxygenase-2 (COX2) and LDL receptor-related protein (LRP1) genes, as well as reduced the expression of monocyte chemoattractant protein (MCP1) gene, compared with a MeD enriched with nuts or with a low-fat diet. In the second, study44, we compared 3-month changes in the whole genome of peripheral blood mononuclear cells. Results of functional annotation analyses showed that from 18 cardiovascular canonical pathways, 9 were modulated by a MeD enriched with VOO and 4 when the MeD was enriched with nuts44. In a sub-study of the EUROLIVE study, we proposed for the first time an integrated scheme for the in vivo downregulation of the CD40/CD40L system and its downstream products promoted by the consumption of VOO45. Our results showed a decrease in the expression of pro-atherogenic genes: CD40 antigen ligand (CD40L), interleukin 23A (IL23A), ADRB2, oxidized LDL (lectin-like) receptor 1 (OLR1), interleukin-8 receptor-a (IL8RA), and IL7R after consumption of VOO high in polyphenols when compared with the refined olive oil, low in polyphenols. The decrease in these genes was concomitant with the decreasing trend of interlinked ones such as vascular endothelial growth factor (VEGF), ICAM-1, and MCP1. In this study45, the reduction in LDL oxidation and the increase in antioxidant polyphenols in LDL promoted by the regular dietary intake of phenolic compound-rich VOO, were associated with a down regulation in the expression of genes related with the CD40/CD40L pathway. Due to all referred above, VOO and its phenolic compounds can modulate the expression of atherosclerosis related genes towards a protective mode in vivo in humans.

Conclusions

We have scientific data providing level I evidence that VOO can promote additional benefits to those of provided by other vegetable oils on risk factors for cardiovascular disease such as lipids and lipid oxidation, inflammation, endothelial dysfunction and systolic blood pressure. At present, the known mechanisms by which VOO can exert these beneficial effects in humans are the increase in the antioxidant content of LDL, and a nutrigenomic effect, modulating towards a protective mode the expression of atherosclerosis-related genes.

Acknowledgements

CIBEROBN is an initiative of the Instituto de Salud Carlos III, Madrid, Spain.
References


